Does heparin improve pregnancy outcomes for women with evidence of placental dysfunction?
ISRCTN | ISRCTN88675588 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN88675588 |
Secondary identifying numbers | N/A |
- Submission date
- 20/03/2007
- Registration date
- 02/05/2007
- Last edited
- 28/09/2009
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Pregnancy and Childbirth
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof John Kingdom
Scientific
Scientific
Department of Obstetrics & Gynecology
700 University Ave, 3rd Floor
Toronto
M5G 1Z4
Canada
jkingdom@mtsinai.on.ca |
Study information
Study design | Randomised controlled open label trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Not specified |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | Does heparin improve pregnancy outcomes for women with evidence of placental dysfunction? A randomised controlled trial |
Study acronym | HEPRIN: HEparin for the PRevention of complications related to placental INsufficiency |
Study objectives | The administration of heparin to women with identified placental dysfunction will: 1. Reduce the risk of intra-uterine foetal death 2. Reduce the risk of other adverse pregnancy outcomes |
Ethics approval(s) | Approval received from the Mount Sinai Hospital (Canada) on the 6th March 2007. |
Health condition(s) or problem(s) studied | Pregnancy; placental dysfunction |
Intervention | Daily subcutaneous heparin (7500 units twice daily from randomisation [18 to 24 weeks gestation] until birth) versus standard care (no medication administered). Follow up was performed on women and their infants up to four months of age; longer term follow up may be possible subject to further successful funding. |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Not Specified |
Drug / device / biological / vaccine name(s) | Heparin |
Primary outcome measure | 1. Intrauterine foetal death 2. Adverse pregnancy complications (including pre-eclampsia, preterm birth, infant small for gestational age, neonatal death) These will be assessed during the antenatal period (in relation to side effects of medication) and after the time of birth for birth and postpartum outcomes. |
Secondary outcome measures | 1. Adverse neonatal outcomes 2. Adverse maternal outcomes 3. Maternal quality of life and emotional wellbeing: this will be assessed at four months postpartum using standard questionnaires (the Edinburgh depression scale; the 36-item Short Form health survey [SF-36] and the Speilberger anxiety trait questionnaires) 4. Placental pathology These will be assessed during the antenatal period (in relation to side effects of medication) and after the time of birth for birth and postpartum outcomes. |
Overall study start date | 21/03/2007 |
Completion date | 28/02/2010 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Female |
Target number of participants | 102 women |
Key inclusion criteria | 1. Women with a singleton pregnancy at 18 to 22 weeks gestation 2. Evidence of placental dysfunction in their current pregnancy as determined by two or more of the following: a. abnormal ultrasonographic placental morphology b. abnormal uterine artery Doppler waveforms c. one or more abnormal biochemical markers on first or second trimester maternal serum screening |
Key exclusion criteria | 1. Women with known positive thrombophilic screening 2. Known lethal foetal anomaly 3. Any contraindication to heparin therapy or continuation of the pregnancy (e.g., chorioamnionitis requiring delivery) 4. Clinical need for heparin therapy during pregnancy (e.g., previous venous thrombo-embolic episode) 5. Multiple pregnancy 6. Hypertension 7. Language barrier requiring official translator |
Date of first enrolment | 21/03/2007 |
Date of final enrolment | 28/02/2010 |
Locations
Countries of recruitment
- Canada
Study participating centre
Department of Obstetrics & Gynecology
Toronto
M5G 1Z4
Canada
M5G 1Z4
Canada
Sponsor information
University of Toronto (Canada)
University/education
University/education
Mt Sinai Hospital
600 University Avenue
Toronto
M5G 1Z4
Canada
Website | http://www.utoronto.ca/ |
---|---|
https://ror.org/03dbr7087 |
Funders
Funder type
Research organisation
The Physicians Services Incorporated Foundation (Canada)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |